Kaixin Zhou, Celine Bellenguez, Chris C A Spencer, Amanda J Bennett, Ruth L Coleman, Roger Tavendale, Simon A Hawley, Louise A Donnelly, Chris Schofield, Christopher J Groves, Lindsay Burch, Fiona Carr, Amy Strange, Colin Freeman, Jenefer M Blackwell, Elvira Bramon, Matthew A Brown, Juan P Casas, Aiden Corvin, Nicholas Craddock, Panos Deloukas, Serge Dronov, Audrey Duncanson, Sarah Edkins, Emma Gray, Sarah Hunt, Janusz Jankowski, Cordelia Langford, Hugh S Markus, Christopher G Mathew, Robert Plomin, Anna Rautanen, Stephen J Sawcer, Nilesh J Samani, Richard Trembath, Ananth C Viswanathan, Nicholas W Wood, Lorna W Harries, Andrew T Hattersley, Alex S F Doney, Helen Colhoun, Andrew D Morris, Calum Sutherland, D Grahame Hardie, Leena Peltonen, Mark I McCarthy, Rury R Holman, Colin N A Palmer, Peter Donnelly, Ewan R Pearson
Metformin is the most commonly used pharmacological therapy for type 2 diabetes. We report a genome-wide association study for glycemic response to metformin in 1,024 Scottish individuals with type 2 diabetes with replication in two cohorts including 1,783 Scottish individuals and 1,113 individuals from the UK Prospective Diabetes Study. In a combined meta-analysis, we identified a SNP, rs11212617, associated with treatment success (n = 3,920, P = 2.9 × 10(-9), odds ratio = 1.35, 95% CI 1.22-1.49) at a locus containing ATM, the ataxia telangiectasia mutated gene...
February 2011: Nature Genetics